ライフサイエンスコーパス: renal transplant

1 ping) and prolonged cold ischemia (syngeneic renal transplant).

2 ving donor (n=427) or deceased donor (n=548) renal transplant.

3 Receipt of a renal transplant.

4 olycystic kidney disease (APKD) in need of a renal transplant.

5 ional methods assessing disease state in the renal transplant.

6 antibodies induced a recurrence of MN in the renal transplant.

7 eas transplant is performed some years after renal transplant.

8 evidence of dialysis (lasting >6 months) or renal transplant.

9 sis in a 66-year-old man who had undergone a renal transplant.

10 junction with either cadaveric or live donor renal transplant.

11 h incident LN-ESRD who were waitlisted for a renal transplant.

12 one required hemodialysis and four underwent renal transplant.

13 tes lifelong immunosuppressive therapy after renal transplant.

14 ls in patients may thus improve prognosis of renal transplants.

15 n fibroblast growth factor-23/KLOTHO axis in renal transplants.

16 rior when compared with well HLA-matched DBD renal transplants.

17 DGF) in patients who received deceased donor renal transplants.

18 cellent visualization of vascular anatomy of renal transplants.

19 oninvasive tool to detect high risk of AR of renal transplants.

20 idney function following IRI and survival of renal transplants.

21 negative long-term outcome in patients with renal transplants.

22 One hundred thirteen consecutive renal transplant 2D and 3D ultrasound examinations were

23 ] age, 56 [19] years), 177 (53.8%) underwent renal transplant; 58 (17.6%), heart transplant; 54 (16.4

24 participating in the Assessment of LEscol in Renal Transplant (ALERT) study.

25 16.3% of renal transplant alone patients required nephrectomy at

26 Here, we used a syngeneic rat renal transplant and IRI model to evaluate the therapeut

27 to be safe and effective for patients after renal transplant and is a promising treatment regimen fo

28 protective role in response to injury after renal transplant and, presumably, in other forms of acut

29 Seven patients received a renal transplant, and among those whose underlying clona

30 4-5 at baseline, and those who had undergone renal transplant before exposure.

31 munohistochemistry revealed US28 in 31 of 34 renal transplant biopsies from HCMV-seropositive donors.

32 Thirty-nine renal transplant biopsies from patients with de novo don

33 Renal transplant biopsies with acute tubular necrosis de

34 in samples from the same routine diagnostic renal transplant biopsy procedure split for FFPE and RNA

35 However, the associations of TRIs in renal transplant biopsy specimens are not known.

36 n, and heat shock protein 47, for ABMR in 53 renal transplant biopsy specimens, including 20 ABMR spe

37 Renal transplant candidates (RTC) with latent tuberculos

38 ancer may be more harmful than protective in renal transplant candidates because it does not appear t

39 of anti-HLA sensitized and highly sensitized renal transplant candidates on waiting lists, and the pr

40 o specific guidelines exist for screening in renal transplant candidates.

41 etrospective multicenter study from 3 French renal transplant centers was conducted, including 123 tr

42 A prospective, observational renal transplant cohort (n = 185; minimum, 5-year follow

43 r each sample across three European ancestry renal transplant cohorts (n = 889) and tested as predict

44 ninety-seven subjects referred for a primary renal transplant completed the questionnaire.

45 reservation on candidate genes included in a renal transplant diagnostic panel.

46 Twelve of 15 patients who received renal transplants during follow-up had both early and fo

47 e information about the processes underlying renal transplant dysfunction and can be used for the dev

48 cause the vasculature is affected in chronic renal transplant dysfunction, US28 may provide a potenti

49 ients not yet on dialysis or for those after renal transplant, early institution of recombinant human

50 tients >/=18 years of age undergoing primary renal transplant evaluation during a 10-year period.

51 ospective study of 1,597 subjects undergoing renal transplant evaluation from June 1, 2006, to March

52 rs associated with rate of completion of the renal transplant evaluation were analyzed using a retros

53 arity as a barrier to successful outcomes in renal transplants for African Americans has been well de

54 Five patients had failed at least 1 previous renal transplant from aHUS.

55 ective study of 594 adults with PCKD who had renal transplants from 1994 to 2014.

56 nterstitial fibrosis may occur abnormally in renal transplants from donations after uncontrolled circ

57 patients, 195 HCV+ recipients (R+) received renal transplants from HCV+ donors (D+), in contrast to

58 ears with CKD (stages 3-5 CKD, dialysis, and renal transplant) from 11 sites in Australia, New Zealan

59 Adverse events were scarce; renal transplant function and proteinuria remained stabl

60 ntrast and thus does not adversely influence renal transplant function.

61 management of TRAS in patients with impaired renal transplant function.

62 Renal transplant glomerulitis (G) is associated with acu

63 66.9 [12.5] years), and 2980 patients in the renal transplant group (27.3% women; 72.7% men; mean [SD

64 in the stage 5D CKD group, and 65.2% in the renal transplant group received in-hospital reperfusion

65 The renal transplant group was more likely to receive reperf

66 isk-adjusted in-hospital mortality among the renal transplant group with STEMI was markedly lower com

67 ients in the non-CKD, stage 5D CKD, or prior renal transplant groups.

68 has progressed to functional impairment of a renal transplant have been defined in clinical biopsy sp

69 ealign the priorities of clinical trials for renal transplant immunosuppression with the current unme

70 ratio (HR) of these outcomes associated with renal transplant in the primary analysis.

71 rinary CXC chemokine ligand (CXCL)10 detects renal transplant inflammation noninvasively, but has lim

72 tients in the Cooperative European Pediatric Renal Transplant Initiative Registry, with an observatio

73 Delayed graft function (DGF) in renal transplant is associated with reduced graft surviv

74 Renal transplant is the treatment of choice for patients

75 splantation among individuals with two prior renal transplants is not described in the literature, an

76 dy-mediated rejection is a leading cause for renal transplant loss.

77 Adults who underwent live donor renal transplant (LRT) + simultaneous BN (SBN) from Augu

78 compared outcomes in pregnancies fathered by renal transplant men per whether they had been exposed t

79 a from the Norwegian Renal Registry with all renal transplanted men alive between January 1, 1995 and

80 During the given time, 230 immunosuppressed renal transplanted men fathered 350 children (155 on MPA

81 (Eld) (>/=60 years) recipients are receiving renal transplants more frequently.

82 ed 1,679 adult, deceased donor, single-organ renal transplants occurring between 2000 and 2012.

83 patients with LN-ESRD were waitlisted for a renal transplant, of whom 5738 (59%) had a transplant.

84 CKD cohort (n=104), identified the effect of renal transplant on serum TMAO concentration in a subset

85 Three groups were analyzed: renal transplant-only recipients (tx alone), recipients

86 f serum creatinine, end-stage renal disease, renal transplant, or renal death.

87 leukocyte antigen loci is known to influence renal-transplant outcome.

88 In children, poorly HLA-matched LD renal transplant outcomes are not inferior when compared

89 jor source of HO-1 and higher levels improve renal transplant outcomes.

90 nsplant immunosuppression is known to affect renal transplant outcomes.

91 nd prognostic values of this measurement for renal transplant pathology and outcome remain unclear.

92 aluation is the gold standard for diagnosing renal transplant pathology.

93 reviously unknown poxvirus rash illness in a renal transplant patient.

94 ion in peripheral blood mononuclear cells of renal transplant patients (r=0.91, P<0.001).

95 ctional, interview study was conducted among renal transplant patients aged 20 to 30 years.

96 auses polyomavirus-associated nephropathy in renal transplant patients and hemorrhagic cystitis in bo

97 r) in a large, inclusive survey (n = 172) in renal transplant patients at a single institution.

98 xpression data in 558 blood samples from 436 renal transplant patients collected across eight transpl

99 Furthermore, analysis of data from 46,691 renal transplant patients in the United Network for Orga

100 levels of catalytic IgG in a large cohort of renal transplant patients over a 2-y period.

101 of predicted alloimmune quiescence in stable renal transplant patients receiving long-term immunosupp

102 Paricalcitol administration to renal transplant patients significantly reduced intact p

103 monitoring (ABPM) for risk stratification in renal transplant patients still remains poorly defined.

104 We evaluated antibody binding of waitlisted renal transplant patients to 3 glycan knockout (KO) pig

105 A retrospective study in all renal transplant patients treated with tacrolimus at our

106 Twenty renal transplant patients were included in this retrospe

107 and HLA-DQ antigens were determined for 703 renal transplant patients who had no detectable donor-sp

108 inct condition which should be considered in renal transplant patients with ascites, after all other

109 y and safety of sofosbuvir and ledipasvir in renal transplant patients with chronic HCV infection.

110 non-smokers were included (40 CsA-medicated renal transplant patients with GO [GO+; n = 20] or witho

111 In preliminary studies, adult renal transplant patients with normal histology (n = 5),

112 om a prospective, observational cohort of 59 renal transplant patients with surveillance or indicatio

113 formulation is similar to Prograf in stable renal transplant patients, but data in de novo patients

114 s that need special attention in the care of renal transplant patients, particularly modifiable facto

115 In renal transplant patients, TCF7L2 rs7903146 is strongly

116 In renal transplant patients, the prevalence of nocturnal h

117 ey allograft survival affecting up to 15% of renal transplant patients.

118 L10 for detecting alloimmune inflammation in renal transplant patients.

119 iovascular risk attributable to BP burden in renal transplant patients.

120 , and kidney biopsies were collected from 48 renal transplant patients.

121 would guide immunosuppression management in renal transplant patients.

122 d GC-MS-based metabolomic study on urines of renal transplant patients.

123 udy, we assessed the outcome of all (n = 95) renal transplanted patients with pretransplant cancer di

124 ABO-incompatible renal transplant performed with antibody removal and con

125 pective review of 7 consecutive living donor renal transplants performed using the RF technique was p

126 The 7 preceding living donor renal transplants performed using the standard arterial

127 then studied in a larger, prospective adult renal transplant population (n = 148 urines from n = 133

128 C virus (HCV) infection is prevalent in the renal transplant population but direct acting antiviral

129 The prevalent renal transplant population presents an opportunity to o

130 rrogate of kidney disease progression in the renal transplant population, as it is in proteinuric nep

131 The other control group comprised the entire renal transplanted population in Uppsala.

132 ell-documented patient cohort (n = 892) in a renal transplant program with protocol biopsies was used

133 We included 310 adult renal transplants receiving twice-daily tacrolimus throu

134 A renal transplant recipient in her 60s presented with a h

135 , we describe the case of a 63-year-old male renal transplant recipient with a remote history of pulm

136 t a rare survival case of isolated GITB in a renal transplant recipient, occurring seven years after

137 Twenty renal transplant recipients (10 rituximab-treated, 10 pl

138 ed 12-hour everolimus (EVL) PK in 16 elderly renal transplant recipients (all whites; 10 men; mean ag

139 epidemiology in a large cohort of pediatric renal transplant recipients (n = 242) and assessed the i

140 mortality, and graft failure in a cohort of renal transplant recipients (n=495, median follow-up 7.0

141 a single-center, prospective cohort study of renal transplant recipients (N=81), urinary clusterin wa

142 intake, with graft failure and mortality in renal transplant recipients (RTR) and potential effect m

143 igh-risk, donor-positive/recipient-negative, renal transplant recipients (RTR).

144 rparathyroidism is reported in 10% to 66% of renal transplant recipients (RTR).

145 g is a risk factor for poor late outcomes in renal transplant recipients (RTR).

146 f pyridoxal 5'-phosphate (PLP) are common in renal transplant recipients (RTRs) and confer increased

147 Renal transplant recipients (RTRs) have commonly been ur

148 cancer (NMSC) is substantially higher among renal transplant recipients (RTRs) than in the general p

149 In renal transplant recipients (RTRs), new-onset diabetes a

150 centrations of pyridoxal-5-phospate (PLP) in renal transplant recipients (RTRs).

151 s, 16 outbreaks occurred, including 13 among renal transplant recipients (RTRs).

152 ssociated with an increased risk of death in renal transplant recipients (RTRs).

153 Arterial hypertension (HT) is common in renal transplant recipients (RTRs).

154 ral blood monocyte cells and CD3+ T cells of renal transplant recipients (RTX) receiving tacrolimus (

155 pheral blood samples from 348 HLA-mismatched renal transplant recipients and 101 nontransplant contro

156 t failure, but large-scale data in pediatric renal transplant recipients and a comprehensive analysis

157 l carcinoma is the most common malignancy in renal transplant recipients and a major cause of morbidi

158 easured routinely for diagnostic purposes in renal transplant recipients and are associated with anti

159 BKPyV is known to cause severe morbidity in renal transplant recipients and can lead to graft reject

160 This study evaluated 664 renal transplant recipients and correlated HLA-DR/DQ sin

161 Renal transplant recipients and dialysis patients were e

162 These data will further inform prospective renal transplant recipients and donors during pretranspl

163 ffects a significant proportion of pediatric renal transplant recipients and is associated with uniqu

164 on accounts for around half of all pediatric renal transplant recipients and results in improved rena

165 reshold value likely needs to be lowered for renal transplant recipients and supports continued use o

166 sured in a longitudinal cohort of 699 stable renal transplant recipients and the associations of T50

167 cells obtained from a new cohort of tolerant renal transplant recipients and those from age- and sex-

168 entify clinically significant de novo DSA in renal transplant recipients and to define the properties

169 Approximately only 50% of renal transplant recipients are alive at 10 years due to

170 differentiated CD8(+) T cells would identify renal transplant recipients at elevated SCC risk.

171 finding could help in the identification of renal transplant recipients at high risk of this cancer,

172 approximately 800 patients in the cohort of renal transplant recipients at our institution, 15 subje

173 ystems patient and claims data for all adult renal transplant recipients between 2000 and 2010 with c

174 Renal transplant recipients beyond 1 month posttransplan

175 be the effects of AL induction therapy on AA renal transplant recipients beyond the first posttranspl

176 Melanoma risk factors and incidence in renal transplant recipients can inform decision making f

177 tation of PTTB and may show delayed onset in renal transplant recipients due to the use of lower dose

178 lled study using C1-INH in highly sensitized renal transplant recipients for prevention of AMR.

179 arge national data registry used a cohort of renal transplant recipients from the United States Renal

180 Nearly one third of pediatric renal transplant recipients had a genetic cause of their

181 Fifty-one (69%) renal transplant recipients had fDGF, of which 14 experi

182 Renal transplant recipients had greater risk of developi

183 ugh the proportion of elderly patients among renal transplant recipients has increased, pharmacokinet

184 There is evidence that renal transplant recipients have accelerated atheroscler

185 Renal transplant recipients have an increased risk of no

186 We analyzed a prospective cohort of renal transplant recipients having routine EBV PCR surve

187 A previous GWAS performed in 300 renal transplant recipients identified two SNPs (rs38113

188 We describe the results of 11 ABOi pediatric renal transplant recipients in the 2 largest centers in

189 or the progression of glucose intolerance in renal transplant recipients in the late posttransplant p

190 This study puts focus on renal transplant recipients in their 80th year or longer

191 Hypertension in renal transplant recipients is common and ranges from 50

192 dity associated with malignancy in long-term renal transplant recipients is due to cutaneous squamous

193 ment of hepatitis C virus (HCV) infection in renal transplant recipients is possible, but limited dat

194 ave been reported in ABO-incompatible (ABOi) renal transplant recipients managed solely with antibody

195 use of hereditary and acquired risk factors, renal transplant recipients manifest features of a chron

196 ) formulation with the original (Prograf) in renal transplant recipients older than 60 years.

197 Homoarginine was measured in 829 renal transplant recipients participating in the placebo

198 estimated glomerular filtration rate, and 23 renal transplant recipients referred for parathyroidecto

199 Notably, BP treatment goals for renal transplant recipients remain an enigma because the

200 proteinuria, diabetes, or CKD stages 1-4 or renal transplant recipients reporting >/=10 ESRD events

201 Our data indicate that elderly renal transplant recipients starting EVL 1 month after t

202 carcinoma development in long-term, at-risk renal transplant recipients than previously identified c

203 was tested on >1000 samples from a cohort of renal transplant recipients to assess its performance in

204 We performed a retrospective analysis of renal transplant recipients treated with rapamycin from

205 , point to the need for careful follow-up of renal transplant recipients undergoing intravitreal ther

206 We recommend that in renal transplant recipients undergoing therapy with intr

207 d standard (iohexol plasma clearance) in 193 renal transplant recipients using concordance correlatio

208 Whether outcomes of MI differ among renal transplant recipients vs patients with stage 5D CK

209 tcomes of ST-segment elevation MI (STEMI) in renal transplant recipients vs the stage 5D CKD group or

210 ousand three hundred seventy-eight pediatric renal transplant recipients were analyzed; 804 (58%) rec

211 Renal transplant recipients were classified as never, fo

212 Five hundred seventy-seven consecutive renal transplant recipients were included.

213 A total of 5983 renal transplant recipients were included.

214 Renal transplant recipients were randomized to receive e

215 Eighty renal transplant recipients were randomized, and 78 were

216 reg cells as an adoptive cellular therapy in renal transplant recipients who are using everolimus (EV

217 etermine risk factors and characteristics of renal transplant recipients who develop melanoma.

218 We retrospectively identified 59 renal transplant recipients who developed dnDSA and had

219 We report 2 cases of renal transplant recipients who developed significant al

220 Adult renal transplant recipients who had symptomatic chronic

221 ulating anti-PLA2R antibodies in a cohort of renal transplant recipients who prospectively developed

222 th a functioning graft (DWFG) is affected in renal transplant recipients who receive prophylaxis for

223 We report our experience treating 43 renal transplant recipients with 4 different DAA regimen

224 A cohort of 596 renal transplant recipients with 50,011 serial tacrolimu

225 Twelve renal transplant recipients with aHUS-related end-stage

226 ted vasculitis, as well as in some groups of renal transplant recipients with alloimmune graft damage

227 57 renal transplant recipients with and 53 without previous

228 Renal transplant recipients with and without previous sq

229 In renal transplant recipients with CKD stages 4 to 5T, pat

230 Retrospective cohort study evaluating renal transplant recipients with first AMR episodes trea

231 Eighty-one renal transplant recipients with FMF-associated AA amylo

232 es from 1 patient with JCPyVAN and 20 stable renal transplant recipients with JCPyV viruria was attem

233 Renal transplant recipients with otherwise unexplainable

234 l but not death-censored renal graft loss in renal transplant recipients with PTDM.

235 deling and mineral loss, and reduced eGFR in renal transplant recipients with secondary hyperparathyr

236 In-hospital mortality rates in renal transplant recipients with STEMI are more favorabl

237 Among renal transplant recipients with STEMI, the use of reper

238 nce to recommend for or against screening of renal transplant recipients within 1 month, patients wit

239 ion, treatment modalities, and outcomes of 7 renal transplant recipients, 1 liver transplant recipien

240 t study and case-control study in 50 de novo renal transplant recipients, 50 chronic kidney disease (

241 We aimed to evaluate this risk score in renal transplant recipients, a population with heightene

242 , we systematically analyzed HDL from stable renal transplant recipients, according to graft function

243 CPyV) is reactivated in approximately 20% of renal transplant recipients, and it may rarely cause JCP

244 is a risk factor for acute rejection (AR) in renal transplant recipients, and KDIGO guidelines sugges

245 ct development of squamous cell carcinoma in renal transplant recipients, and undertook a prospective

246 isease remains the leading cause of death in renal transplant recipients, but the underlying causativ

247 apy for Pneumocystis pneumonia prevention in renal transplant recipients, reported adverse drug react

248 compartments from 20 HCMV-infected patients (renal transplant recipients, stem cell transplant recipi

249 pective cohort study of 2749 adult Norwegian renal transplant recipients, transplanted between 1999 a

250 From 1988 consecutive renal transplant recipients, we analyzed 179 patients un

251 comparing fluvastatin with placebo in stable renal transplant recipients, were genotyped for all SNPs

252 (PVAN) occurs in a significant percentage of renal transplant recipients, with BK virus reactivation

253 s were found in urine samples from 19 stable renal transplant recipients, with JCPyV quasispecies det

254 A antibodies (dnDSA) may cause graft loss in renal transplant recipients.

255 nt in the patient with JCPyVAN and in stable renal transplant recipients.

256 ependent of plasma HDL cholesterol levels in renal transplant recipients.

257 rence in this cohort of long-term, high-risk renal transplant recipients.

258 ed with better patient and graft survival in renal transplant recipients.

259 ffness, oxidative stress, or inflammation in renal transplant recipients.

260 fness, oxidative stress, and inflammation in renal transplant recipients.

261 transplant immune surveillance for pediatric renal transplant recipients.

262 ally in the increasing population of elderly renal transplant recipients.

263 ogression of kidney failure and mortality in renal transplant recipients.

264 e comparable to those previously reported in renal transplant recipients.

265 and OGTT were performed in 1,619 nondiabetic renal transplant recipients.

266 alent to the original formulation in elderly renal transplant recipients.

267 mmunohistochemically TAg-positive UCs in two renal transplant recipients.

268 ld and clinical utility of WES for pediatric renal transplant recipients.

269 -INT was evaluated in 2055 biopsies from 775 renal transplant recipients.

270 mplications occur in almost 1 in 5 pediatric renal transplant recipients.

271 gnificantly associated with DGF in pediatric renal transplant recipients.

272 s, correlates with delayed graft function in renal transplant recipients.

273 genic factor of urothelial carcinoma (UC) in renal transplant recipients.

274 t-line Pneumocystis pneumonia prophylaxis in renal transplant recipients.

275 latacept could be the treatment of choice in renal-transplant recipients with renal dysfunction attri

276 cept in 29 human leukocyte antigen-immunized renal-transplant recipients.

277 iii) metaanalysis of lung adenocarcinoma and renal transplant rejection transcriptomics.

278 8-mediated T-cell costimulation and prevents renal transplant rejection.

279 CAD) system for the early detection of acute renal transplant rejection.

280 Renal transplants remain a medical challenge, because th

281 Renal transplant resolves HPT in 56.9% of patients at 2

282 pporting the indication for PHPI in the post-renal transplant setting.

283 Renal transplant-specific risk factors have not been est

284 tem for a reliable non-invasive diagnosis of renal transplant status for any DW-MRI scans, regardless

285 es after deceased donor but not living donor renal transplants, thus donor death and organ preservati

286 mother had previously presented with a post-renal transplant TMA.

287 lerogenic, we tested the hypothesis that the renal transplant transient chimerism protocol would indu

288 Three prospective pig-to-baboon renal transplants using kidneys from swine delivered by

289 dimensional (3D) ultrasound in evaluation of renal transplant vasculature compared to 2-dimensional (

290 First renal transplant was analyzed as a time-varying exposure

291 Renal transplant was associated with a survival benefit,

292 on with subsequent prioritized allocation of renal transplant was endorsed in selected cases.

293 y exposure posed a concern, as our patient's renal transplant was identified as the infection source.

294 Renal transplant was marked by a drastic decrease in lev

295 rospective chart review of consecutive adult renal transplants was conducted between 2006 and 2014.

296 Fifty pediatric renal transplants were performed from 1/2009-12/2014.

297 drug exposure in monkeys was established and renal transplants were then performed using PRCL-02 mono

298 Two patients who had received renal transplants while inpatients in an adjacent ward d

299 Patients with renal transplants who received a diagnosis of melanoma a

300 d proteinuria in 43 consenting recipients of renal transplants with secondary hyperparathyroidism.